This event is a one-of-a-kind, interactive forum where top diligence experts will discuss best practices and strategies for executing a proper IP due diligence analysis, both for your own portfolio, and that of potential targets.

Over the past few years, with many blockbuster drug patents expiring, R&D pipelines drying up, and the evolving challenges for patenting life-sciences inventions, many have coined the current landscape as “anti-patent.” As a result, there has been steady increase in companies looking to collaborate and do deals to protect their assets, maintain market share, and maximize the life of their patent portfolios.

In response to challenging patent landscape surrounding the pharmaceutical, biotechnology, and medical device industries, ACI has pioneered a conference tailored specifically to professionals involved with intellectual property due diligence for life sciences inventions. Our Life Sciences IP Due Diligence Summit is a one-of-a-kind gathering place for key stakeholders to learn the best strategies and tips to map out and conduct a successful and cost-effective due diligence analysis.

Agenda and speakers list will be available soon. Stay up-to-date by signing up for email updates.

Don’t miss this opportunity to benchmark your IP diligence strategies with top industry representatives.
Register now and enjoy early bird savings!


  • AMRI
  • Akin Gump Strauss Hauer & Feld LLP
  • Allergan plc
  • Arnold & Porter Kaye Scholer LLP
  • AtriCure Inc
  • Axinn Veltrop & Harkrider LLP
  • BA Ruskin Law LLC
  • BONWRx
  • Beck & Thomas
  • Biogen
  • Blaze Bioscience Inc
  • Boehringer Ingelheim GmbH
  • Boehringer Ingelheim International GmbH
  • Brammer Bio
  • Brinks Gilson & Lione
  • Cantor Colburn LLP
  • Carlson Caspers Vandenburgh Lindquist & Schuman PA
  • Centre for Drug Research and Development
  • Charles River Associates Inc
  • Choate Hall & Stewart LLP
  • Cipla Limited
  • Clark & Elbing LLP
  • Codiak BioSciences
  • DRI Capital Inc
  • Dentsply Sirona Inc
  • Dr. Reddys Laboratories
  • Drinker Biddle & Reath LLP
  • Duane Morris LLP
  • Eisai Inc
  • Evolve BioSystems
  • Finnegan Henderson Farabow Garrett & Dunner
  • Fish & Richardson
  • Fitzpatrick Cella Harper & Scinto
  • Foghorn Therapeutics
  • Forma Therapeutics Inc
  • Futuragene
  • Genentech Inc
  • Gibson Dunn & Crutcher LLP
  • Gilead Sciences
  • Green Griffith & Borg-Breen LLP
  • Heliae
  • Hikma Pharmaceuticals USA Inc
  • Houlihan Lokey
  • Hueschen & Sage PLLC
  • Immunogen Inc
  • Indivior Inc
  • Intellia Therapeutics Inc
  • Ipsen Bioscience Inc
  • Ironwood Pharmaceuticals Inc
  • Jazz Pharmaceuticals
  • Johnson-IP Strategy & Policy Consulting
  • Jounce Therapeutics Inc
  • KSQ Therapeutics Inc
  • King & Spalding LLP
  • Leason Ellis LLP
  • MEDRx
  • Marshall Gerstein & Borun LLP
  • Mayer Brown LLP
  • McDonnell Boehnen Hulbert & Berghoff LLP
  • Merchant & Gould
  • Merck & Co
  • MicroVention Inc.
  • Norris McLaughlin & Marcus P.A.
  • Novartis
  • Novartis Institutes For Biomedical Research
  • Novartis Pharmaceuticals
  • Obalon Therapeutics
  • Ohlandt Greely Ruggiero & Perle LLP
  • Paul Hastings LLP
  • Pearne & Gordon LLP
  • Pepper Hamilton LLP
  • Pieris Pharmaceuticals Inc
  • Porzio Bromberg & Newman P.C.
  • Purdue Pharma LP
  • Purdue Research Foundation
  • Regeneron Pharmaceuticals Inc
  • Roivant Sciences Inc
  • Ropes & Gray LLP
  • Rutgers Law School
  • Sarepta Therapeutics
  • Shire Pharmaceuticals
  • SmartPharm Therapeutics
  • Squire Patton Boggs Us LLP
  • Steptoe & Johnson LLP
  • Sterne Kessler Goldstein & Fox
  • Sun Pharmaceutical Industries Ltd
  • Taro Pharmaceutical Industries
  • Teva Pharmaceuticals
  • Transformative
  • US Court of Appeals for Federal Circuit
  • University of California
  • VBI Vaccines Inc
  • VLP Law Group LLP
  • Wave Life Sciences
  • Wilson Sonsini Goodrich & Rosati PC

Hear what past participants have to say about this one-of-a-kind event:

“Unique high level sessions, good mix of in-house and outside counsel”

“Hearing from professionals involved in due diligence on a daily basis was very informative.”

“Great panels, lots of diversity of practice, and lots of seasoned practitioners”

“The design of the event brought us all together along with room intimacy”

“High quality and level of conversations”

“Awesome- Interactive and thorough information”

“Good focused discussions covering all aspects”

You May Also Be Interested In:

Paragraph IV Disputes Master Symposium

Meet and network with the key influencers shaping the law, policy and proceedings of Hatch-Waxman litigation.

October 3 – 4, 2019
Chicago, IL

Event Contacts

For sponsorship opportunities please contact:

American Conference Institute
[email protected]

For media partnership opportunities please contact:

Linda Lam
T: 212-352-3220 ext. 5538
[email protected]

For questions about this year’s program/content, or information on how you can speak next year please contact:

Lilli Seidman Davis
T: 212-352-3220 ext. 5529
[email protected]

Connect With Us